Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-08-09
2002-05-28
Fonda, Kathleen K. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S183000, C514S186000, C540S473000, C540S474000
Reexamination Certificate
active
06395725
ABSTRACT:
TECHNICAL FIELD
This invention relates to the treatment of humans and lower animals in pain management: to prevent or relieve pain, to prevent or reverse tolerance to opioid analgesics and hyperalgesia associated with prolonged opioid treatment, and to prevent or reduce symptoms of opioid withdrawal and related withdrawal syndromes.
BACKGROUND ART
Numerous analgesics are known to medical science. Many analgesics fall into one of two large categories—nonsteroidal analgesic/anti-inflammatory drugs (NSAIDs) and opioids. NSAIDs operate by inhibiting cyclooxygenase enzymes and thereby the synthesis of prostaglandins. Prostaglandins sensitize pain receptors, lowering the pain threshold and making normal stimuli, such as touch and stretch sensations, painful. NSAIDs can be quite effective at returning the lowered pain threshold to normal but do not elevate the pain threshold.
A second class of pain relievers, opioids or opioids, operate by mimicking natural peptides such as enkephalins and endorphins to stimulate one or more of the &mgr;-, &dgr;- and &kgr;- receptor systems in the nervous system. Opioids elevate the pain threshold so that normally painful stimuli are perceived as less painful or even euphoric. Opioids are commonly used in the clinical management of severe pain, including chronic severe pain of the kind experienced by cancer patients.
Capsaicin and its derivatives operate by depleting local stores of substance P, a neuropeptide involved in the transmission of pain impulses and are used in several OTC analgesic products.
Each of these classes of compounds has inherent problems and limitations. The opioid analgesics are antagonized by analogous N-allyl compounds such as naloxone; the NSAID analgesics are not. NSAIDs that are nonselective for the cyclooxygenase 2 produced in inflammation (COX-2) also inhibit constitutive cyclooxygenase 1 (COX-1), causing undesirable damage to the gastric mucosa. They have limited effectiveness as analgesics in lowering an elevated threshold to normal and are generally used for mild to moderate pain. They are also ineffective drugs for elevation of the pain threshold above normal levels, which prevents their use in pain such as surgical pain where an underlying pathological condition has not elevated the pain threshold.
Opioids have problems with tolerance and dependency, so that over a course of therapy increasing dosages of compound are required to achieve the same level of analgesia, and cessation of opioid administration when analgesia is no longer needed elicits a withdrawal syndrome with unpleasant and potentially serious symptoms. The dependency and withdrawal syndrome both make it difficult for the clinician to discontinue opioid therapy even when the opioids are no longer effective in relieving pain because of the development of tolerance. Narcotic induced hyperalgesia (NIH) can also develop in association with tolerance to the opioids. All of these factors limit the usefulness of opioids in the management of chronic severe pain, despite their potency.
No adequate strategy has been devised to overcome the development of opioid tolerance and provide an ongoing approach to the management of chronic severe pain. Mechanisms of tolerance are not well understood but are known to involve the NMDA receptor, since the NMDA receptor antagonist MK-801 has been shown in rats to prevent morphine tolerance. NMDA stimulates nitric oxide synthase (NOS) and NOS has been observed histochemically in tissues that contain opioid receptors and are important in the pain response, such as the amygdala, cortical gray matter, and the substantia gelatinosa of the spinal cord. Non-selective NOS inhibitors such as NG-nitroarginine prevent and reverse morphine tolerance. However, nonselective inhibition of NOS is associated with a vast array of undesirable side effects, including hypertension, increased platelet and white blood cell reactivity, decreased cerebral blood flow, and gastrointestinal and renal toxicity.
Capsaicin and some of its derivatives, in addition to producing analgesia, also elicit a burning sensation. This effect is responsible for the pungency of hot peppers (Capscum spp.) and limits the applicability of many members of this series of compounds.
For these and other reasons, a continuing need exists for new high potency analgesics. A need also exists for methods for reversing tolerance to opioid analgesics so that patients who require these drugs for pain over extended periods can do so without loss of potency and efficacy.
One object of this invention is to provide new methods for the prevention and relief of mild to severe pain by identifying a new biological activity of a class of synthetic catalyst compounds, and by specifying a new indication for those compounds.
It is another object of this invention to provide methods for preventing and reversing tolerance to opioid analgesics by identifying another new biological activity of that class of catalysts and another new indication for those compounds.
These and other objects of the invention will be evident from the following disclosure.
REFERENCES:
patent: 4877561 (1989-10-01), Iga et al.
patent: 4999347 (1991-03-01), Sorenson
patent: 5541174 (1996-07-01), Sorenson
patent: 5637578 (1997-06-01), Riley et al.
patent: 1088086 (1992-12-01), None
patent: 0 524 161 (1993-01-01), None
patent: WO 94/15925 (1994-07-01), None
patent: WO 96/39396 (1996-12-01), None
patent: WO 97/33877 (1997-09-01), None
Del Villano, et al., “Elevated Superoxide Dismutase in Black Alcoholics,” 1980,(Science, vol. 207 pp. 991-993.
Huber et al., “Superoxide Dismutase Pharmacology and Orgotein Efficacy: New Perspectives.” 1980, Dev. Bochem. vol. 11B, pp. 395-407.
Lengfelder, et al., “Superoxide Dismutation by Low Molecular Weight Cu-Complexes,” 1981, Bull Europ Physiopath. Resp., vol. 17 pp. 73-80.
Joyave, et al., “Alteration of Chemically Induced Hepatotoxicity by Copper (II) (3,5-Diisopropylsalicylate)2,” 1985, Biochemical Pharmacology, vol. 34, No. 21, pp. 3915-3919.
“Modified Superoxide Dismutase as Inflammation Inhibitor and Others,” 1989, (Chemical Abstracts, vol. 111, No. 15) p. 353.
Okuyama, et al., “Copper Complexes of Non-steroidal Antiinflammatory agents: Analgesic Activity and Possible Opioid Receptor Activation1,” 1987, Agents and Actions, vol. 21, 1/2, pp. 130-144.
Varsano, et al., “Superoxide Dismutase Activity in Morphine-and Meperidine-Addicted Mice and Their Response to Paraquat Poisoning,” 1992, (FEBS) pp. S54-S59.
Shuff, et al., “Stable Superoxide Dismutase (SOD)-Mimetic Ternary Human Serum Albumin-Cu(II)(3,5-Diisopropylsalicylate)4Complexes in Tissue Distribution of the Binary Complex,” 1992, Biochemical Pharmacology, vol. 43, No. 7, pp. 1601-1612.
Kohút, et al., “Effect of Allopurinol and Superoxide Dismutase on Indomethacin-Induced Gastric Lesions in the Rat,” 1993, Physiol. Res., vol. 42. pp. 273-276.
Lin, et al., “Use of Superoxide Dismutase (SOD) in Patients with Temporomandibular Joint Dysfunction—a Preliminary Study,” 1994, Int. J. Oral Maxillofac. Surg., vol. 23, pp. 428-429.
Mao et al., “Mechanisms of hyperalgesia and Morphine tolerance: a current view of their possible interactions,” 1995, Pain, vol. 62, pp. 359-274.
Elmer, et al., “Transgenic Superoxide Dismutase Mice Differ in Opioid-Induced Analgesia,” 1995, European Journal of Pharmacology, vol. 283, pp. 227-232.
Goldstein, et al., “Exogenous Gaseous Superoxide Potentiates the Antinociceptive Effect of Opioid Analgesic Agents,” 1996, Inflamm Res., vol. 45, pp. 473-478.
The Merck Index, Twelfth Edition, S. Budavari, editor. Merck & Co., Inc., Whitehouse Station, NJ, 1996 pp. 1540-1541, monograph 9177.
M. Tal, “A Novel Antioxidant Alleviates heat Hyperalgesia in Rats with an Experimental Painful Peripheral Neuropathy,” 1996, NeuroReport, vol. 7, pp. 1382-1384.
Li, et al., “Synthesis and Pharmacological Activites of 1,1-Dialkyl-4 (3-Bromopropoionyl) Piperazinium Bromides,” 1996, Acta Pharmacetica Sinica, vol. 31, pp. 757-760.
De Raeve et al., “Decreased Cu,Zn-SOD activity in asthmatic airway epithelium: corection by inhaled corticost
Fonda Kathleen K.
G.D. Searle & Co.
Senniger Powers Leavitt & Roedel
LandOfFree
Analgesic methods using synthetic catalysts for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Analgesic methods using synthetic catalysts for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analgesic methods using synthetic catalysts for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2910535